Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284551 | 0.80 | — | — | |
| SCHEMBL10284553 | 0.79 | ALDH1A1 (0.30) | — | |
| SCHEMBL27738563 | 0.77 | IDO1 (0.52) | FDPSIDO1 | |
| SCHEMBL28218974 | 0.75 | ALDH1A1 (0.36) | EPHX2NR1H4 | |
| SCHEMBL20856571 | 0.72 | TSHR (0.45) | FDPSIDO1 | |
| SCHEMBL14256893 | 0.72 | MEN1 (0.49) | — | |
| SCHEMBL15256594 | 0.71 | TDP1 (0.37) | IDO1 | |
| SCHEMBL27341065 | 0.70 | MRGPRX4 (0.53) | FDPS | |
| SCHEMBL16959914 | 0.69 | PIK3CA (0.41) | FDPSIDO1 | |
| SCHEMBL20856347 | 0.69 | ALDH1A1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | FDPS 4068/4885IDO1 945/4885EPHX2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.